Statins Close Obesity's Cholesterol Gap, Study Finds
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- A Lancet study analyzing data from 110 health surveys (1990–2024) covering nearly 1 million adults aged 20–79 across England, Japan, South Korea, Taiwan, Thailand, Finland, and the US found that differences in non-HDL cholesterol and systolic blood pressure between people with obesity and those with a normal BMI have "narrowed or disappeared," especially in adults over 40.
- Prof Majid Ezzati of Imperial College London's School of Public Health said cholesterol- and blood-pressure-lowering medications have helped middle-aged and older adults reduce cardiovascular risk to levels similar to people with normal BMI — a baseline relevant for the growing population prescribed weight-loss drugs.
- Older adults with obesity in England, the US, Thailand, South Korea, and Japan became "indistinguishable from, or better off than" those with normal BMI on the two key cardiometabolic metrics, a convergence researchers attribute to higher statin and antihypertensive use among people with obesity.
- Adults under 40 with obesity still showed higher levels of unhealthy cholesterol and blood pressure than their normal-weight peers, prompting co-author Yse d'Ailhaud de Brisis to call for earlier lifestyle interventions, screening, and medication in this younger group.
- Prof Bryan Williams, chief scientific and medical officer at the British Heart Foundation, called the findings "a powerful public health success story" but cautioned that obesity still raises risk for diabetes, kidney disease, and some cancers beyond the two metrics studied.
Why it matters: With millions now being prescribed GLP-1 weight-loss drugs, the study offers a cardiovascular baseline — showing that statins and antihypertensives have already closed the cholesterol/blood pressure gap for older adults with obesity in five of seven countries studied, while younger adults under 40 remain unprotected by that same medication effect and still carry elevated risk.
